Skip to main content
Top
Published in: Medical Oncology 5/2014

01-05-2014 | Short Communication

Dose adjustment of carboplatin in patients on peritoneal dialysis

Authors: Achuta K. Guddati, Parijat S. Joy, Creticus P. Marak

Published in: Medical Oncology | Issue 5/2014

Login to get access

Abstract

The Calvert equation has been extensively used to determine the dosage of carboplatin. However, in patients on dialysis, it predicts the same dosage regardless of the frequency of dialysis. Clearance of carboplatin during hemodialysis has been studied to a lesser extent, but there have been very few studies which have investigated the clearance of carboplatin in patients on peritoneal dialysis. A mathematical formula is proposed here to predict the dose of carboplatin for a given AUC in patients on peritoneal dialysis. This formula takes into account the frequency of dialysis sessions and the time delay between carboplatin infusion and the initiation of dialysis. The formula predicts an approximately similar dosage of carboplatin as that of the Calvert formula in patients undergoing peritoneal dialysis four times per day if dialysis is initiated 12 h after infusion. The formula may help in guiding the adjustment of carboplatin dose in patients who receive a lesser number of dialysis sessions per day and in those patients whose dialysis is initiated at different times (0–24 h) after carboplatin infusion. It is suggested that usage of this formula will result in a better dosage of carboplatin to suit specific dialysis frequencies in specific patients and eventually may result in a better efficacy and toxicity profile.
Appendix
Available only for authorised users
Literature
1.
go back to reference Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant. 2005;20(12):2587–93. doi:10.1093/ndt/gfi159.PubMedCrossRef Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant. 2005;20(12):2587–93. doi:10.​1093/​ndt/​gfi159.PubMedCrossRef
2.
go back to reference Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354(9173):93–9.PubMedCrossRef Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354(9173):93–9.PubMedCrossRef
3.
go back to reference Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748–56.PubMed Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748–56.PubMed
5.
go back to reference Heijns JB, van der Burg ME, van Gelder T, Fieren MW, de Bruijn P, van der Gaast A, et al. Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment. Cancer Chemother Pharmacol. 2008;62(5):841–7. doi:10.1007/s00280-007-0671-9.PubMedCentralPubMedCrossRef Heijns JB, van der Burg ME, van Gelder T, Fieren MW, de Bruijn P, van der Gaast A, et al. Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment. Cancer Chemother Pharmacol. 2008;62(5):841–7. doi:10.​1007/​s00280-007-0671-9.PubMedCentralPubMedCrossRef
Metadata
Title
Dose adjustment of carboplatin in patients on peritoneal dialysis
Authors
Achuta K. Guddati
Parijat S. Joy
Creticus P. Marak
Publication date
01-05-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 5/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0946-z

Other articles of this Issue 5/2014

Medical Oncology 5/2014 Go to the issue